NEW YORK (GenomeWeb News) – Bristol-Myers Squibb has renewed its license for Ingenuity Systems’ pathway analysis software for use in genomics and proteomics research aimed at advancing its drug discovery programs, Ingenuity said today.
 
Under the agreement, Bristol-Myers Squibb gains enterprise-wide access to the Ingenuity Pathways Analysis software for modeling, visualization, and interpretation of genomics and proteomics data. BMS has been an Ingenuity customer since 2004.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.